FEC (5-Fluorouracil-Epirubicin-Cyclophosphamide) Monthly Versus FEC Weekly in Metastatic Breast Cancer: First results of a randomized trial

References

• Anonymous Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer. An Italian multicentre breast study with epirubicin. J Clin Oncol 1988; 6: 976–82
   PubMed Web of Science ®Google Scholar
• Group FES. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French Epirubicin Study Group. J Clin Oncol 1988; 6: 679–88
   PubMedGoogle Scholar
• Group TFES. A prospective randomized trial comparing epirubicin monotherapy to two-fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. The French Epirubicin Study Group. J Clin Oncol 1991; 9: 305–12
   PubMedGoogle Scholar
• Lopez M, Papaldo P, Di Lauro L, Vici P, Carpano S, Conti E M. 5–fluorouracil, adriamycin, cyclophosphamide (FAC) vs. 5–fluorouracil, epirubicin, cyclophosphamide (FEC) in meta-static breast cancer. Oncology 1989; 46: 1–5
   PubMed Web of Science ®Google Scholar
• Rivarola E G, Cuneo N, Orsini W, et al. Adriamycin (ADM) vs epirubicin (EPI) combination (FAC vs FEC), for advanced breast cancer (BC). Comparison of clinical activity and sub-clinical cardiotoxicity (SCTY) (meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1987; 6: A203
   Google Scholar
• Cattaneo S., Barni G, Paolorossi F, Lissoni P, Crispino S, Tansini G. Advanced breast cancer in patients with a poor performance status (PS): A new schedule treatment with 4′-epidoxorubicin (meeting abstract). Fed of European Cancer Societies, Madrid 1987; 128
   Google Scholar
• Beex L, Speth P V, Hoestel Q, et al. Weekly low dose 4 epiadriamycin as second line chemotherapy in postmenopausal patients with advanced breast cancer (meeting abstract). Fed of European Cancer Societies, Madrid 1987; 150
   Google Scholar
• Beretta G, Locatelli C, Tabiadon D, Labianca R, Fraxschini P, Luporini G. Epirubicin treatment of advanced breast carcinoma with the weekly low-dose regimen. Oncology 1987; 44: 6–12
   PubMedGoogle Scholar
• Castiglione M, Schatzman E, Goldhirsch A., et al. Adriamycin (A) vs epirubicin (E): Low-dose weekly schedule in metastatic breast cancer. Preliminary results of tumor response and of quality-of-life measurements. Proc Annu Meet Am Soc Clin Oncol 1990; 9: A182, meeting abstract
   Google Scholar
• Creech R H, Catalano R B, Shah M K. An effective low-dose adriamycin regimen as secondary chemotherapy for metastatic breast cancer patients. Cancer 1980; 46: 433–7
   PubMedGoogle Scholar
• Elomaa I, Blomqvist C, Rissanen P. Weekly low-dose doxorubicin as second line therapy in advanced breast cancer. Acta Oncol 1988; 27: 799–801
   PubMed Web of Science ®Google Scholar
• Frenay M, Milano G, Francois E, et al. Phase II trial of weekly low dose doxorubicin in advanced breast cancer: Clinical and pharmacokinetic results. Proc Annu Meet Am Soc Clin Oncol 1988; 7: A102, meeting abstract
   Google Scholar
• Gasparini G, Dal Fior S, Panizzoni G A, Favretto S, Pozza F. Weekly epirubicin versus doxorubicin as second line therapy in advanced breast cancer. A randomized trial. Am J Clin Oncol 1991; 14: 38–41
   PubMedGoogle Scholar
• Gundersen S, Kvinnsland S, Klepp O, Kvalöy S, Lund E, Höst H. Weekly adriamycin versus VAC in advanced breast cancer. A randomized trial. Eur J Cancer Clin Oncol 1986; 22: 1431–4
   PubMedGoogle Scholar
• Gundersen S, Kvinnsland S, Klepp O, Lund E, Höst H. Weekly adriamycin vs. 4-epidoxorubicin every second week in advanced breast cancer. A randomized trial. The Norwegian Breast Cancer Group. Eur J Cancer 1990; 26: 45–8
   PubMedGoogle Scholar
• Namer M, Khater R, Hery M, Frenay M. Weekly low dose adriamycin in poor prognosis patients with advanced breast cancer (meeting abstract). Breast Cancer Res Treat 1986; 8: 92
   Google Scholar
• Nylén U, Baral E, Svane G, Rutqvist L E. Weekly doxorubicin in the treatment of metastatic breast carcinoma. Acta Oncol 1989; 28: 515–7
   PubMed Web of Science ®Google Scholar
• Scheithauer W, Zielinski C, Ludwig H. Weekly low dose doxorubicin monotherapy in metastatic breast cancer resistant to previous hormonal and cytostatic treatment. Breast Cancer Res Treat 1985; 6: 89–93
   PubMed Web of Science ®Google Scholar
• Scheulen M E, Niederle N, Scmidt C G. Weekly low-dose (WLD) epirubicin (Epi) treatment of metastatic breast cancer (BC) (meeting abstract). Proc Annu Meet Am Assoc Cancer Res 1987; 28: 197
   Google Scholar
• Sigurdsson H, Johansson-Terje I, Aspegren K, Landberg T. Weekly-dose doxorubicin (WDA) in advanced breast cancer. Radiother Oncol 1986; 7: 133–9
   PubMedGoogle Scholar
• Tucci E, Algeri R, Guarneri A, et al. Weekly epirubicin in advanced breast cancer. Tumori 1988; 74: 689–92
   PubMedGoogle Scholar
• Twelves C J, O'Reilly S M, Coleman R E, Richards M A, Rubens R D. Weekly epirubicin for breast cancer with liver metastases and abnormal liver biochemistry. Br J Cancer 1989; 60: 938–41
   PubMed Web of Science ®Google Scholar
• Cersosimo R J, Hong W K. Epirubicin: A review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue. J Clin Oncol 1986; 4: 425–39
   PubMed Web of Science ®Google Scholar
• Torti F M, Bristow M R, Howes A E, et al. Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. Ann Intern Med 1983; 99: 745–9
   PubMed Web of Science ®Google Scholar
• Brincker H. Distant recurrence in breast cancer. Survival expectations and first choice of chemotherapy regimen. Acta Oncol 1988; 27: 729–32
   PubMed Web of Science ®Google Scholar
• Jones W G. Effective palliation of advanced breast cancer with weekly low dose epirubicin. Eur J Cancer Clin Oncol 1989; 25: 357–60
   PubMedGoogle Scholar
• Ebbs S R.J. A.S, Graham H. A, Hern R P, Bates T, Baum M. Advanced breast cancer. A randomized trial of epidoxorubicin at two different dosages and two administration systems. Acta Oncol 1989; 28: 883–5
   PubMedGoogle Scholar
• Becher R, Kurschel E, Kloke O, et al. Randomized study of epirubicin and cyclophosphamide in advanced breast cancer. Proc Annu Meet Am Soc Clin Oncol 1988; 7: A125, meeting abstract
   Google Scholar
• Hortobagui G N, Yap H P, Kau S W, et al. A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer. Am J Clin Oncol 1989; 12: 57–62
   PubMedGoogle Scholar
• Jouve M, Palangie T, Dorval T, et al. Metastatic breast cancer: Randomized trial comparing equivalent monthly doses of chemotherapy (FAC-V) given either in an intensive 3–day course or in a 5–day two-weekly regimen. Proc Annu Meet Am Soc Clin Oncol 1988; 7: A114
   Google Scholar
• Canellos G P, Pocock S J, Taylor S G, Sears M E, Kladsen D J, Band P R. Combination chemotherapy for metastatic breast carcinoma. Prospective comparison of multiple drug therapy with L-phenylalanine mustard. Cancer 1976; 38: 1882–6
   PubMed Web of Science ®Google Scholar
• Carmo-Pereira J, Costa F O, Henriques E, et al. Advanced breast carcinoma: A comparison of two dose levels of adriamycin (A) (meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1986; 5: 56
   Google Scholar
• Ejlertsen B, Pfeiffer P, Pdersen D, et al. Diminished efficacy by reducing duration of CEF from 18 to 6 mo in the treatment of metastatic breast cancer. Proc Annu Meet Am Soc Clin Oncol 1990; 9: A82, meeting abstract
   Google Scholar
• A'Hern R P, Ebbs S R, Baum M B. Does chemotherapy improve survival in advanced breast cancer ? A statistical overview. Br J Cancer 1988; 57: 615–8
   PubMed Web of Science ®Google Scholar